Bariatric surgery often produces remission of hyperglycaemia in patients with coexistent obesity and type 2 diabetes mellitus, but the hyperglycaemia is prone to return years later. A prospective study demonstrates that therapy with a glucagon-like peptide 1 receptor agonist can reinstate normal glycaemic control in many of these patients.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Rubino, F. et al. Metabolic surgery in the treatment algorithm for type 2 diabetes: a joint statement by international diabetes organizations. Diabetes Care. 39, 861–877 (2016).
Schauer, P. R. et al. Bariatric surgery versus intensive medical therapy for diabetes — 5-year outcomes. N. Engl. J. Med. 376, 641–651 (2017).
Adams, T. D. et al. Weight and metabolic outcomes 12 years after gastric bypass. N. Engl. J. Med. 377, 1143–1155 (2017).
Steinert, R. E. et al. Ghrelin, CCK, GLP-1, and PYY(3–36): secretory controls and physiological roles in eating and glycemia in health, obesity, and after RYGB. Physiol. Rev. 97, 411–463 (2017).
Nannipieri, M. et al. Roux-en-Y gastric bypass and sleeve gastrectomy: mechanisms of diabetes remission and role of gut hormones. J. Clin. Endocrinol. Metab. 98, 4391–4399 (2013).
Hutch, C. R. & Sandoval, D. The role of GLP-1 in the metabolic success of bariatric surgery. Endocrinology 158, 4139–4151 (2017).
Lim, S., Kim, K. M. & Nauck, M. A. Glucagon-like peptide-1 receptor agonists and cardiovascular events: class effects versus individual patterns. Trends Endocrinol. Metab. 29, 238–248 (2018).
Bailey, C. J. & Marx, N. Cardiovascular protection in type 2 diabetes: insights from recent outcome trials. Diabetes Obes. Metab. 21, 3–14 (2019).
Gorgojo-Martínez, J. J., Feo-Ortega, G. & Serrano-Moreno, C. Effectiveness and tolerability of liraglutide in patients with type 2 diabetes mellitus and obesity after bariatric surgery. Surg. Obes. Relat. Dis. 12, 1856–1863 (2016).
Miras, A. D. et al. Adjunctive liraglutide treatment in patients with persistent or recurrent type 2 diabetes after metabolic surgery (GRAVITAS): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. https://doi.org/10.1016/S2213-8587(19)30157-3 (2019).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bailey, C.J. Treating T2DM and obesity with bariatric surgery and GLP1 agents. Nat Rev Endocrinol 15, 504–506 (2019). https://doi.org/10.1038/s41574-019-0240-4
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41574-019-0240-4